Tharimmune Unveils Phase 2 Study for TH104 and Business Progress

Tharimmune, Inc. has announced a Phase 2 study for TH104, targeting moderate-to-severe pruritus associated with primary biliary cholangitis (PBC). The company aims to address this rare condition with no known cure. This follows favorable Phase 1 results and positive regulatory feedback from the EMA and FDA. The trial, set for 2025, will involve 40 participants across the U.S. and Europe. The study will assess TH104's safety, tolerability, and efficacy in itch reduction.

In 2024, Tharimmune achieved several milestones, including validating TH104's manufacturing supply, presenting clinical data, and entering significant licensing agreements to enhance its immunology pipeline. Notably, the company raised over $4 million through private placements, bolstering its clinical development initiatives.

Tharimmune appointed Sanam Parikh to its Board of Directors, expanding expertise in clinical trial management. This aligns with the company's strategic goals to advance its oncology-focused pipeline.